Case study
Elucidating A2A Receptor Activation Pathways: A Study by Acellera and UCB in GPCR Drug Discovery
All case studies


The A2A receptor, a GPCR associated with cardiovascular and neurological disorders, presents significant potential for therapeutic development. However, the inherent challenges in determining GPCR structures due to their flexibility have long been an obstacle. In a collaborative effort, Acellera and UCB have made significant strides in this area through the application of advanced simulation technologies.

Collaborative Approach by Acellera and UCB

In this collaborative study, Acellera's expertise in molecular dynamics (MD) simulations and Markov State Modelling (MSM) was combined with UCB's rich experience in drug development. This synergistic approach leveraged adaptive sampling and a goal-oriented scoring function to reconstruct the A2A receptor's activation pathway. This method marks a significant improvement over traditional techniques, offering an unbiased and comprehensive view of the receptor's behavior.

Key Findings and Implications

The collaboration between Acellera and UCB has yielded several important insights:

  • Diverse Metastable States: The research identified various metastable states within the A2A receptor, enriching our understanding of its activation and signaling pathways.
  • Ligand-Competent States: The study successfully highlighted specific agonist-competent and G-protein competent states, crucial for the development of targeted therapeutic agents.
  • Influence of Cholesterol: A novel aspect of the research was the discovery of cholesterol's influence on receptor activation, suggesting potential areas for allosteric modulation in drug design.

Concluding Remarks

This joint effort by Acellera and UCB represents a significant advancement in the field of structure-based drug discovery. The insights gained from this study not only enhance our understanding of the A2A receptor but also pave the way for more efficient and targeted drug development strategies. For the pharmaceutical industry, this collaboration demonstrates the value of combining advanced simulation technologies with drug development expertise to address complex challenges in drug discovery.

About the Collaboration

Acellera, founded in 2006 and a pioneer in utilizing GPU technology for molecular dynamics, brings a computational approach to drug discovery. UCB, with its extensive background in pharmaceutical development, complements Acellera's technological expertise. This partnership underscores a shared commitment to innovation and a dedication to transforming drug discovery into a computable, more predictable task.